<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="65511">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01978938</url>
  </required_header>
  <id_info>
    <org_study_id>TP-434-010</org_study_id>
    <nct_id>NCT01978938</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections</brief_title>
  <official_title>A Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Tetraphase Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Tetraphase Pharmaceuticals, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 3, Randomized, Double-Blind, Double-Dummy, Multicenter, Prospective Study to
      Assess the Efficacy and Safety of Eravacycline Compared with Levofloxacin in Complicated
      Urinary Tract Infections (cUTI)
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2013</start_date>
  <primary_completion_date type="Anticipated">February 2015</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Clinical and microbiological response vs failure</measure>
    <time_frame>at the Post-Treatment (PT) visit (defined as 6-8 days after the completion of therapy)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary objective is to demonstrate that eravacycline is non-inferior to levofloxacin in responder outcome (clinical and microbiological response vs failure) in the micro-ITT population at the Post-Treatment (PT) visit (defined as 6-8 days after the completion of therapy).
NOTE: For the EMA, the primary analysis populations will be the microbiologically evaluable (ME) and clinically evaluable (CE) populations.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">840</enrollment>
  <condition>Complicated Urinary Tract Infections (cUTI)</condition>
  <arm_group>
    <arm_group_label>Eravacycline IV and oral</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eravacycline 1.5 mg/kg IV q24h plus eravacycline 250 mg PO BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Levofloxacin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Levofloxacin 750 mg PO QD + placebo PO QD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eravacycline 1.5 mg/kg, plus eravacycline 200 mg PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eravacycline 1.5 mg/kg IV q24h plus eravacycline 200 mg PO BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eravacycline</intervention_name>
    <arm_group_label>Eravacycline IV and oral</arm_group_label>
    <arm_group_label>Eravacycline 1.5 mg/kg, plus eravacycline 200 mg PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <arm_group_label>Levofloxacin</arm_group_label>
    <other_name>Levaquin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  1. Male and female subjects with either:

             a. Pyelonephritis and normal urinary tract anatomy (no more than 30% of the total
             population), OR b. cUTI with at least one of the following conditions associated with
             a risk for developing cUTI: i. Indwelling urinary catheter ii. Urinary retention
             (approximately 100 mL of residual urine after voiding) iii. Neurogenic bladder iv.
             Partial obstructive uropathy (eg, nephrolithiasis, bladder stones, and ureteral
             strictures) v. Azotemia of renal origin (not CHF or volume related) such that the
             serum BUN is elevated (&gt; 20 mg/dL) AND the serum BUN:creatinine ratio is &lt; 15 vi.
             Surgically modified or abnormal urinary tract anatomy (eg, bladder diverticula,
             redundant urine collection system, etc.) EXCEPT surgery within the last month

        Exclusion Criteria:

          -  1. Concurrent use of non-study antibacterial drug therapy that would have a potential
             effect on outcome evaluations in subjects with cUTI, including:

               1. Subjects with a history of a levofloxacin-resistant urinary tract infection

               2. Likely to receive ongoing antibacterial drug prophylaxis prior to the LPT visit
                  (eg, subjects with vesiculo-ureteral reflux)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Kevin Lloyd</last_name>
    <phone>617-715-3589</phone>
    <email>klloyd@tphase.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>San Diego Clinical Trials</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Mohamed Bidair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbor-UCLA Medical Center</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90505</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Brad Spellberg, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tampa General Hospital</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33606</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Orban, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Columbus Regional Research Institute</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>31904</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Subich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ohio State University Wexner Medical Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>, MD</last_name>
    </contact>
    <investigator>
      <last_name>Christian Jones, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 3, 2014</lastchanged_date>
  <firstreceived_date>October 28, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Urinary Tract Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
